Panelists discuss how clinical trials in multiple myeloma can be improved to better reflect real-world scenarios and patient outcomes, emphasizing the importance of end points such as progression-free survival, overall survival, and quality of life measures, while also considering ways to increase trial inclusivity and applicability to diverse patient populations.
Carrie Koenigsfeld, PharmD, FAPhA, discusses the CDC’s recommendation for an RSV vaccine for all adults aged 75 years and older, as well as those aged 60 to 74 years at increased risk, and outlines the conditions that elevate the risk for severe illness, including the implications of severe illness, such as hospitalization, long-term effects, complications, comorbidities, and mortality, while also comparing how RSV infection affects older vs younger adults.
Panelists discuss how the introduction of triplet therapy prior to transplant in studies like IFM 2009 and DETERMINATION shifted the clinician mindset toward more intensive induction regimens, leading to a focus on achieving deeper responses and longer progression-free survival as primary goals of therapy for newly diagnosed multiple myeloma patients.
Naoto T. Ueno, MD, PhD, FACP, discussed the role of the Hawaiʻi Cancer Consortium to advance trial and treatment efforts for patients with cancer.
Courtney VanHouzen, PharmD shares insights about the community bispecific program at Munson Healthcare.
Shirish Gadgeel, MD, discusses the promising results of the randomized phase 3 HARMONi-2/AK112-303 study comparing ivonescimab to pembrolizumab in PD-L1–positive advanced non-small cell lung cancer.
Longer-term data from the phase 3 MARIPOSA trial confirm superior outcomes of a chemotherapy-free amivantamab-vmjw plus lazertinib regimen compared to osimertinib monotherapy as first-line therapy.
Two MUSC pharmacists describe how pharmacists are often the educational resource for patients and can help when removing certain barriers to care.
At the 2024 World Conference on Lung Cancer, Ana Baramidze, MD, PhD, presented 5-year outcomes of the trial, which investigated cemiplimab monotherapy in first-line advanced non–small cell lung cancer (NSCLC) with PD-L1 expression of 50% or greater.
At the 2024 World Conference on Lung Cancer, Benjamin Besse, MD, PhD, discussed the findings of the phase 3 CARMEN-LCO3 trial, which led to the discontinuation of the study drug by the manufacturer.
Teresa Messick, PharmD discusses how meeting patients “where they are” and supporting them holistically through medication and beyond is the most rewarding part of the profession.
The discussion explores how Medicare's Part D smoothing program in 2025 might impact chronic lymphocytic leukemia patients’ access to and adherence to Bruton tyrosine kinase inhibitor therapies and how pharmacists can help navigate this new program. The session concludes with closing remarks.
Carrie Koenigsfeld, PharmD, FAPhA, discusses an overview of RSV, including its transmission, incidence, seasonality, and clinical presentation.
Panelists discuss how various patient characteristics, including age, fitness level, cytogenetic risk, and comorbidities, influence their decision to use more intensive quadruplet regimens like D-VRd (daratumumab plus bortezomib, lenalidomide, and dexamethasone) vs standard triplet regimens, such as VRd or KRd (carfilzomib, lenalidomide, and dexamethasone) in transplant-eligible multiple myeloma patients, while also considering administration logistics and supportive care requirements
Panelists discuss how transplant eligibility significantly influences first-line treatment goals and initial therapy selection in multiple myeloma, often leading to more intensive induction regimens aimed at achieving deep remissions.
As American Pharmacists Month begins, Alan Corley talks the importance of pharmacists and the value of the profession personally and to the overall community.
The benefits of the daratumumab-based regimen were seen in all patients, including those with high and standard cytogenic risk levels.
Karen Merrill discusses her experiences in pharmacy with plans to celebrate her niece, a first-year pharmacist.
C. diff survivor and Peggy Lillis Foundation Board Member Maryann Webb discusses how her experience with the infection encouraged her to advocate for patients who are struggling to advocate for themselves.
Alan Corley, pharmacy owner in Greenville, TN, reflects on the changes he's witnessed throughout his career and the most rewarding aspects of his profession.
The discussion addresses the economic impact of appropriate dose modifications on chronic lymphocytic leukemia management.
The discussion covers when to consider transitioning to a new therapeutic option in CLL and the factors that influence the decision between dose modification and switching therapies.
Ashraf Badros, MBCHB, discussed new data from the AURIGA study presented at the International Myeloma Society 2024 Annual Meeting, happening September 25 through 29 in Rio de Janeiro, Brazil.
The trial is evaluating ciltacabtagene autoleucel (cilta-cel, Carvykti; Johnson & Johnson) in patients with relapsed and lenalidomide-refractory multiple myeloma.
Ashraf Badros, MBCHB, discussed findings from the AURIGA study being presented at the International Myeloma Society 2024 Annual Meeting, happening September 25 through 29 in Rio de Janeiro, Brazil.
Banerjee also discussed data being presented at the International Myeloma Society 2024 Annual Meeting that he is particularly excited for this year.
The CEPHEUS trial also highlights the importance of minimal residual disease (MRD) as a study end point.
Using biosimilars and generics as well as getting patients connected with manufacturer copay assistance or grant programs can reduce their out-of-pocket costs.
Panelists discuss how their institutions approach frontline treatment for transplant-eligible multiple myeloma patients, typically using a combination of novel agents like proteasome inhibitors and immunomodulatory drugs, followed by autologous stem cell transplantation and maintenance therapy, while considering factors such as patient characteristics and treatment response to guide therapy sequencing.
Panelists discuss how the current first-line treatment options for transplant-eligible patients with newly diagnosed multiple myeloma (NDMM) typically involve combination therapies including proteasome inhibitors, immunomodulatory drugs, and steroids.
